Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Jorge Reis-Filho


United States of America

Memorial Sloan Kettering Cancer Center
New York

Jorge S. Reis-Filho, MD PhD FRCPath, holds a joint medical degree from University of Porto, Portugal and Universidade Federal do Parana, Brazil. After finishing his histopathology training at the Institute of Molecular Pathology and Immunology, University of Porto, Portugal, he did his PhD on breast cancer molecular pathology at the Breakthrough Research Centre where he was appointed Team Leader of the Molecular Pathology Laboratory in 2006. In 2007, Dr Reis-Filho was awarded the CL Oakley Lectureship by the Pathological Society of Great Britain and Ireland and the BACR Translational Research Award. In 2010, Dr Reis-Filho was awarded the 2010 Ramzi Cotran Young Investigator Award by the United States and Canadian Academy of Pathology and the Future Leaders Prize by Cancer Research UK. Dr Reis-Filho is the youngest ever Fellow of The Royal College of Pathologists to have become a member by published works. In 2012, Professor Reis-Filho took the position of Member at the Department of Pathology and Affiliate Member of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Centre in New York, USA, and in 2016, he was appointed Director of Experimental Pathology.

Dr Reis-Filho has published over 410 peer reviewed articles, is an associate editor of the Journal of the National Cancer Institute and the Journal of Pathology, and a senior scientific advisor for Science Translational Medicine.

Dr Reis-Filho’s research interests are in the development of a predictive breast cancer classification system based on the oncogenic drivers of special histologic types of breast and salivary gland cancers, and in the understanding of the causes and impact of intra-tumour genetic heterogeneity in cancers. His group has approached these aims using a combination of traditional pathology approaches with high-throughput genomics methods. He has led projects that resulted in the development of novel single cell sequencing methods that can be applied to formalin-fixed paraffin-embedded samples, and has employed these methods to investigate the impact of intra-tumour genetic heterogeneity in the progression from in situ to invasive breast cancer. His team is also exploring circulating cell-free plasma DNA and cell-free cerebrospinal fluid DNA sequencing approaches as biomarkers for disease monitoring and as a means to combat the challenges posed by intra-tumour genetic heterogeneity.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.